http://medconferencestoday.com

Breaking Medical Conference News...

Biologists, Educators Recognize Excellence In Evolution Education

The National Association of Biology Teachers (NABT) will recognize Dr. Randy Moore, a professor of biology at the University of Minnesota, with the 2008 Evolution Education Award during the NABT annual conference to be held 15-18 October 2008 in Memphis, Tennessee. The Evolution Education Award is cosponsored by the American Institute of Biological Sciences (AIBS) and the Biological Sciences Curriculum Study (BSCS).

Lancashire Scheme To Encourage Next Generation Of Health And Social Care Workers Wins A Top Training Accolade, England

The Central Lancashire Health and Social Care Cadet initiative was awarded a 2008 National Training Award in the North West regional finals for partnership and collaboration. Run by UK Skills on behalf of the Department for Innovation, Universities and Skills, these awards are the UK's most prestigious accolade for excellence in training and people development. The Cadet scheme is a training initiative that prepares 16 to 20 year olds for a career in health and social care.

The Health Of The Nation: Focus Of University Of Bath Conference

Teenage mental health, childhood obesity and the dangers of an over-indulgent lifestyle are amongst the topics discussed at the annual School for Health Research Matters conference on Friday 19 September. This event showcased some of the diverse research activity taking place throughout the School for Health that is influencing policy at a regional, national and international level.

Pharmalef Inc. is starting collaboration in development of new oral delivery platform

Pharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.
(613) 686-5745 Cerepotec Pharmalef

CDISC Awarded Contract For Training Of FDA Reviewers

The Clinical Data Interchange Standards Consortium (CDISC), announced today that the Food and Drug Administration (FDA) selected CDISC, via a formal RFP process, to provide training to FDA reviewers of regulatory submissions. The courses to be taught over the next two years will include CDISC Basics, the CDISC Study Data Tabulation Model (SDTM), the CDISC Analysis Data Model (ADaM) and Advanced Topics on CDISC Standards.

Whiplash Management Gets Education Boost, Royal Australian College Of General Practitioners

The Royal Australian College of General Practitioners (RACGP) has launched a new online learning activity designed to support general practitioners and other members of the practice team in managing whiplash associated disorders. The activity was developed in conjunction with the University of Sydney with an educational grant from the Motor Accidents Authority of New South Wales and is now available through the RACGP's online education portal gplearning at

Medical Students Open Up To Epocrates

For the third consecutive year, future physicians speak out on the quality of medical training and failing healthcare system. Technology is also top of mind for today's medical students, who are seven times more likely to call on an electronic resource than a colleague or teacher with a medical question, and strongly support the use of electronic medical records in practice. Conducted by Epocrates, Inc.

Anestvice Inc. Phase II Clinical Trials for PC-LM Device have been successfully completed.

The research was conducted on 24 patients ranging in age from 13 to 74 years (the average age was 46.6 ±5.4), who underwent surgery in the urology clinic of the Rostov State Medical University. It was sponsored by Anestvice Inc...
(613) 686-5745 Cerepotec Pharmalef

Events Seek To Raise Health Awareness Among Blacks; Magazine Ranks Top Schools For Hispanic Medical Students

The following summarizes events related to reducing racial health care disparities. Portland, Ore.: Portland Community College's Cascade Campus on Saturday will host a conference that focuses on memory and aging in the black community, the

Virtual Reality Lab Enhances Surgeons' Skills

Virtual reality is making Dr. Angela Gucwa a better surgeon. Before she goes into the operating room, she spends several hours a week honing her skills in the Medical College of Georgia Virtual Education and Surgical Simulation Laboratory. "You become familiar with a lot of the different instruments," says Dr. Gucwa, a second-year surgical resident.

Virtual Reality System Gives Surgeons A New Way To Train

Pilots use flight simulators to train, now surgeon get their own virtual reality system to practice complex procedures. Seattle-based Mimic Technologies developed a training simulator, the dV-Trainer, designed to allow efficient, on-demand training for surgeons learning to use the daVinci® Surgical System, a sophisticated robotic platform that enables complex surgery using a minimally invasive approach.

The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity.

The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity.
(613) 686-5745 Cerepotec Pharmalef

Calling For Nominations For The First BMJ Group Awards

The BMJ Group (British Medical Journal) today reveals the 10 categories of the first inaugural BMJ Group Awards which will recognise and celebrate excellence in health care across the globe. The BMJ Group Awards ceremony will take place on Thursday 2 April 2009 in London, presented by broadcaster and comedienne Sandi Toksvig.

Urgent Need To Train More GPs, Australian Medical Association

AMA President, Dr Rosanna Capolingua, today called on the Government to immediately lift the cap on general practice training places, after it was revealed that more than 200 would-be GPs will be turned away. The Australian Institute of Health and Welfare reported today that patients' access to GPs in Australia has fallen since 2002. Dr Capolingua said patients are telling doctors it is becoming more difficult to get an appointment.

Professor Of Radiology At University Of Cincinnati Receives Neuroradiology Society's Highest Honor

The American Society of Neuroradiology (ASNR) recently awarded Robert Lukin, MD, the organization's highest honor: the Gold Medal. The University of Cincinnati (UC) professor of radiology and former chair accepted the award at the society's annual meeting in New Orleans. The Gold Medal was established in 1995 to honor individuals who have made "exceptional contributions" to the field of neuroradiology.

Espoir Bridge Recruiters has a well established database of over 60,000 candidates all over the world

Espoirbridge www.espoirbridge.com consultants have a wealth of knowledge and experience in Clinical Research, Data Management, Quality Assurance, Regulatory Affairs and all aspects of Information Technology and Office Support.
(613) 686-5745 Cerepotec Pharmalef

New Dates For Medical Reporting Training Courses Announced, UK

Mobile Doctors announces new dates for its 'Excellence in Report Writing' training in response to demand from GPs and specialists. Mobile Doctors, one of the UK's leading providers of medical evidence, is pleased to announce a host of new dates for its 'Excellence in Report Writing' courses, which provide training to General Practitioners (GPs) and specialists in how to compile medico-legal reports and give evidence in court.

Residency Training Study Sees Greater Benefit From Time In The Clinic

A new approach to internal medicine residency training could improve patient care and physician-patient relationships, according to a University of Cincinnati (UC) study. Eric Warm, MD, associate professor of medicine and lead investigator of the study, says research showed residents who spent increased time in outpatient settings as opposed to the hospital delivered a higher quality of care and had more satisfaction in their duties.

Funding To Support Child Witness To Violence Project

Boston Medical Center has received a one-year grant for $50,000 from The Avon Foundation to support the Child Witness to Violence Project (CWVP) a counseling, advocacy and outreach program that focuses on young children who are bystanders to community and domestic violence. CWVP will use the grant to create a partnership to train police officers to better recognize and respond to children affected by violence.

ClinQua Inc: Regulatory Agencies Do Not Require Clinical Trials To Be Expensive!

Mr. David Mills former ClinQua Clinical Trials Inc. www.clinqua.com executive argues that the inevitable burden of clinical investigation is cost, and unfortunately, the weight of that burden falls onto consumers...
(613) 686-5745 Cerepotec Pharmalef

Training Program That Teaches Parents How To Discuss Sex With Children Effective, Study Says

A new training program that teaches parents at their workplace how to discuss sex with their children could be an effective way to reduce high-risk sexual behavior among teenagers, according to a U.S. study published Thursday in the British Medical Journal, Reuters reports.

Online Education Boosts Immunisation Skills For Practice Nurses, Australia

The Royal Australian College of General Practitioners (RACGP), in association with the Australian Practice Nurses Association (APNA) and the Australian Government Department of Health and Ageing (DoHA), has launched six new online learning activities aimed at practice nurses and other members of practice teams to boost their immunisation knowledge. The activities are for free and are available through the RACGP's online education portal gplearning at www.gplearning.com.au.

Academic Health Centers Should Take Lead In Promoting The Sharing Of Biomedical Research Data

Academic health centers (AHCs) have a critical role in enabling, encouraging, and rewarding the sharing of biomedical research data, say a team of academics in this week's PLoS Medicine. "The leaders of medical schools and academic-affiliated hospitals," they say "can play a unique role in supporting this transformation of the research enterprise.

Anestvise Inc. is Delivering Quality and Enabling Technology

Anestvice Inc. www.anestvice.com sponsors clinical trials towards manufacture of new medical devices...
(613) 686-5745 Cerepotec Pharmalef

Increased Support For Hematology-Related Training Programs

The American Society of Hematology (ASH) is proud to announce the inaugural recipients of its Alternative Training Pathway Grant. The grant is given to training program directors to encourage the development and implementation of novel hematology-related training programs. Thomas Abshire, MD, of Emory University, Donald Mahoney Jr.

Launch Of New Interactive Renal Anaemia Resource For Physicians

EPG Health Media, developers of e-communication and clinical information solutions for the health sector, announced the launch of a new interactive Renal Anaemia Knowledge Centre within the web-based physician resource www.epgonline.org.

New Business And Communication Skills Course From British Dental Association

A new BDA Masterclass seminar to help dentists and their teams enhance the patient experience, perfect their communications skills and develop more effective business plans is to be launched by the British Dental Association (BDA). The event, Advanced business and communication skills for dental practices, will be led by top-flight speakers from the world-respected Henley Business School.

CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published

A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof.
(613) 686-5745 Cerepotec Pharmalef

Missed Opportunities For Empathy In Interactions With Lung Cancer Patients

Physicians seldom responded empathetically to the concerns of patients with lung cancer in a small study released on September 22, 2008 in Archives of Internal Medicine, one of the JAMA/Archives journals. The authors of the study initially highlight the importance of empathy in the bedside interaction.

Health Professions Council Launches Consultation On The Standards Of Education And Training And Guidance, UK

The Health Professions Council has launched its consultation on the revised standards of education and training (SETs) and revised standards of education and training guidance. The standards of education and training are the standards against which the HPC assesses education and training programmes. An education and training programme which meets the SETs allows a student who completes that programme successfully to meet our standards of proficiency.

Book To Help Nursing Students Authored By Rutgers College Of Nursing Professor

Robert Atkins, a Rutgers College of Nursing faculty member, has authored a book to help nursing students make the most of their learning opportunities in nursing school. "Getting the Most from Nursing School: A Guide to Becoming a Nurse," presents recommendations from nursing faculty and nurses who have decades of experience that will help students become more successful in nursing school.

Kriger Courses Are Indispensable To Break Into The Biopharmaceutical And Clinical Research Industry.

From what many of our students have said, Kriger www.kriger.com and their professional development courses are not only inspiring but also indispensable when trying to start a career in the biopharmaceutical and clinical research industry.
(613) 686-5745 Cerepotec Pharmalef

Families More Satisfied When Life Support Withdrawal Is Prolonged

According to an article published in the second October 2008 issue of the American Journal of Respiratory and Critical Care Medicine, doctors in intensive care units (ICUs) often withdraw life support systems over a prolonged period of time as they attempt to balance the difficult needs of their patients and the families of patients.

Simulated Cancer Treatment Room For Radiotherapy Students At Kingston And St. George's Universities, London

Radiotherapy students at Kingston University and St George's, University of London are set to be among the first in the country to hone their clinical skills in a simulated cancer treatment room. They will start the academic year completing practical elements of their course in a new Virtual Environment for Radiotherapy Training (VERT) suite, which now takes pride of place in the two institutions' joint Faculty of Health and Social Care Sciences.

Center For Dental Studies Successfully Completes $1M Grant Phase

The California Center for Advanced Dental Studies (CCADS) has successfully completed its first graduating class of doctors. Fifteen doctors from all over Northern California have completed a unique ten month educational program designed to advance their clinical skills in the area of cosmetic dentistry. Along with other recipients worldwide, educational grants in the amount of $18,500 were awarded to each doctor in this select group.

ClinQua Inc. is one of CRO's focusing the Investigator on aspects critical for validating the drugs' therapeutic benefits.

ClinQua Inc. www.clinqua.com is one of CRO's (Contract Research Organizations), who specialize in evaluating the demands of the trial and eliminating redundant protocols and focusing the Investigator on aspects critical for validating the drugs' therapeutic benefits.
(613) 686-5745 Cerepotec Pharmalef

Teaching Health-Care Professionals: Internet-Based Instruction Found To Be Effective

A study led by a team of education researchers from Mayo Clinic and published in the Journal of the American Medical Association (JAMA) concludes that Internet-based education generally is effective. Lead author David Cook, M.D., an associate professor of medicine who practices general internal medicine at Mayo Clinic, worked with researchers from Mayo and McMaster University in Hamilton, Ontario. They reviewed more than 200 studies about Internet-based instruction.

Medical Students Nationwide Remove Conflicts Of Interest - 5th Annual National PharmFree Week Underway, USA

Medical students across the country are celebrating the 5th Annual National PharmFree Week, "Promoting Evidence-Based Practice, Preserving Pharmaceutical Innovation," which allows them to educate themselves and their colleagues about reclaiming the ethics of medicine by removing conflicts of interest and restoring the patient-physician relationship.

Effect Of Coaching And Retesting On Selection Tests Used For Admission To An Australian Medical School

The selection of students for entry to medical schools in Australia is a high-stakes contest. A recent study reported in the latest issue of the Medical Journal of Australia showed that more than half the applicants trying to gain a place at an Australian medical school had attended coaching, and some had repeated selection tests, in order to boost their chances of admission.

Legal Issues in Clinical Research

Bruce Kriger, CEO of Kriger Research Group International www.kriger.com, leading training institution and clinical research organization told in the interview to our edition that one hundred years ago, any doctor could prepare a new medication without any external approval.
(613) 686-5745 Cerepotec Pharmalef

Recipient Of Halpin Foundation-ASN Research Grant Anounced By The Halpin Foundation And The ASN

The Halpin Foundation and the American Society of Nephrology (ASN) proudly announce the recipient of the Halpin Foundation-ASN Research Grant for 2008, which was created to provide funding for young faculty to foster evolution to an independent research career by providing transition funding toward successful application for an RO1 grant. This year's recipient is Elena Torban, PhD. Dr.

Philips And The Specialized Academy For Medical Training Collaborate On Education And Training Program

Royal Philips Electronics (NYSE: PHG; AEX: PHI) and the Specialized Academy for Medical Training (SAMT) announced, that they will work together to provide medical education and training programs for young Saudi high school graduates and staff in hospitals and medical centers across the Kingdom of Saudi Arabia. It is expected that several programs will be implemented from October 2008 onwards, covering medical technology disciplines including X-ray, Ultrasound and Healthcare IT.

British Medical Association Criticises Cuts To Student Grants

Medical student leaders today (Wednesday, 29th October 2008) attacked the government's decision to cut financial support to thousands of students in England from next year. The changes announced today in a written parliamentary answer by the Universities Secretary John Denham, will see reductions in the number of students who will be able to receive annual financial grants.

ClinQua Inc. : The overall cost of clinical trials depends on an array of factors

In a progressive global market of supply and demand, it remains unthinkable to engage in practices that are ambitiously over-priced when there are endless opportunities to utilize more cost-efficient methods which would yield the same results.
(613) 686-5745 Cerepotec Pharmalef

Global Opportunities For Medical Students Recognised

The University of Queensland's School of Medicine has been recognised for its provision of innovative programs in outward mobility and student exchange. The School of Medicine won the Excellence in Outward Mobility award in the 2008 Queensland Education and Training International (QETI) awards last week.

New Doctors Need To Be Aware When Taking Consent, Medical Protection Society Advises

New doctors should not feel pressured to do anything beyond their knowledge, expertise and competence, such as taking consent for a procedure they are not familiar with. Always get a senior to explain it as part of your training, the Medical Protection Society (MPS) advises today. The GMC's recently published guidance on consent reflects a changing medicolegal environment which poses new challenges for doctors.

Ross University Responds To U.S. Primary Care Crisis - Two-Thirds Of Medical Graduates Choose Primary Care Specialty

Overwhelming numbers of Ross University School of Medicine graduates are responding to a deepening healthcare crisis by choosing to go into primary care. Without the crucial contributions of Caribbean institutions like Ross University, the fragile U.S. healthcare system would collapse. A survey by the Journal of the American Medical Association reports that only two percent of U.S. graduating medical students plan to work in primary care.

Anestvice Pressure Controller (APC) – device for maintaining of precisely set pressure in the cuff of Laryngeal Mask (LM) and Endotracheal Tube (ETT) during the surgery

Anestvice ( www.anestvice.com )Pressure Controller (APC) – device for maintaining of precisely set pressure in the cuff of Laryngeal Mask (LM) and Endotracheal Tube (ETT) during the surgery...
(613) 686-5745 Cerepotec Pharmalef

U.S. Medical School Enrollment Reaches Record High; Enrollment Up Among Hispanic Students

Medical school enrollment in 2008 increased 1.6% over last year, resulting in a record-high 18,036 first-year medical students, according to a study by the Association of American Medical Colleges, Bloomberg reports.

UMAT Training Courses Slammed By The Australian Medical Students' Association

Training courses for the Undergraduate Medical Admissions Test (UMAT) are expensive, inequitable and don't improve students' chances of getting into medicine, according to  the Australian Medical Students' Association (AMSA). The courses, which cost anywhere from a few hundred dollars to over $1,700, are purported to improve students' performance in the UMAT and therefore their chances of getting into undergraduate medicine.

Supporting Future Doctors - GMC Seeks Views On Medical Students' Health Issues

The General Medical Council (GMC) and the Medical Schools Council (MSC) have launched a consultation on a new section in guidance about how medical students' health can affect their fitness to practise. The guidance, Medical students: professional behaviour and fitness to practice was successfully published by the GMC and MSC in 2007.

Clinical Research Professionals are Still in Demand despite the World Economic Crisis

Despite the world economic crisis, the clinical research field is currently expanding faster than the introduction of newly qualified professionals that inevitably creates a demand. Most people are under the impression that the barriers to enter this industry are extremely difficult to overcome, but the truth is that everybody working in this industry had to start somewhere and as the industry grows positions need to be filled.
(613) 686-5745 Cerepotec Pharmalef

Tree Of Life Award Received By Jefferson Doctor

Edith P. Mitchell, M.D., clinical professor, Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University and associate director of Diversity Programs for the Kimmel Cancer Center at Jefferson, was recently honored with a 'Tree of Life' award from The Wellness of You, a local nonprofit health education and resource organization. The Tree of Life award recognizes health professionals who are committed to making a difference in community health.

Specialist Library For Surgery, Theatres And Anaesthesia Annual Evidence Update, UK

The NHS National Library for Health Specialist Library for Surgery, Theatres and Anaesthesia provides the latest quality assured evidence-based guidance for all theatre staff supporting the patient through perioperative care.

Nation's Medical Students Seek Essential End Of Life Care Skills

The American Medical Student Association (AMSA), the nation's largest, independent medical student organization, announces the commencement of the AMSA Foundation-VITAS End of Life Education Fellowship Program in which six medical students will be introduced to end of life (EOL) care issues.

CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published

A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof.
(613) 686-5745 Cerepotec Pharmalef

Educating Chief Residents About Addiction At Boston Medical Center

Researchers from Boston Medical Center (BMC) have found that education on addiction is inadequate during medical training, resulting in suboptimal medical care for those at risk. However, the research also found that a Chief Resident Immersion Training (CRIT) program in addiction medicine is an effective "train the trainers" model for dissemination of addiction knowledge and skills to generalist physician trainees. These findings appear in the Journal of General Internal Medicine.

Plymouth Hospitals To Lead Cancer Surgery Training Programme, England

Plymouth Hospitals NHS Trust has been chosen to co-ordinate the national programme for the training of existing consultants in advanced keyhole surgery for the treatment of bowel cancer. The Department of Health has appointed Consultant General Surgeon, Mr Mark Coleman as the National Clinical Lead for the Laparoscopic Colorectal Cancer Surgery Training Programme.

GPs Boost Cancer Screening Skills, Australia

The Royal Australian College of General Practitioners (RACGP) has launched a new online learning activity designed to support general practitioners in boosting their knowledge about the latest approaches to the early detection of common types of cancer including breast cancer, cervical cancer, melanoma, lung cancer, ovarian cancer, prostate cancer and bowel cancer.

The Difference Between GCP Certification and CRA Certification

As per Bruce Kriger, CEO of Kriger Research Group International www.kriger.com , leading training institution and clinical research organization, Good Clinical Practice Guidelines is a general document used by various clinical research professionals who perform different functions in clinical research.
(613) 686-5745 Cerepotec Pharmalef

New Book Helps Medical Students Master Clinical Skills

For medical students who spend years studying textbooks in preparation for written exams on theoretical concepts, it can be rather intimidating to prepare for a test on practical skills used in the clinic. The third edition of a best-selling book that helps medical students prepare for these daunting practical-skills tests, Clinical Skills for OSCEs, was recently released by Scion Publishing.

National Pathology Week 3-9 November - Royal College Of Pathologists

The Royal College of Pathologists and other specialist societies are holding the first National Pathology Week from 3-9 November 2008 to promote pathology. Over 150 fun free events are being held in hospitals and communities all over the United Kingdom and include interactive workshops, laboratory tours, stands in shopping centres, art competitions, quizzes and even a touring pathology bus.

Bridging Public And Private Research On Bioinformatics And Proteomics

The European BioAlpine Convention 2008, an international event organised by the trinational Transalpine Biocluster - Rhône-Alpes (France), Piemonte (Italy) and Western Switzerland -will bring together researchers and professionals from academia and industry in order to present and discuss the most recent findings in the fields of Bioinformatics and Proteomics.

Anestvise Inc. is Delivering Quality and Enabling Technology

Anestvice Inc. www.anestvice.com sponsors clinical trials towards manufacture of new medical devices...
(613) 686-5745 Cerepotec Pharmalef

Medical Students' Association Applauds National's Voluntary Bonding Scheme For Medical Graduates, New Zealand

The New Zealand Medical Students' Association (NZMSA) welcomed the announcement by John Key of the National party's Voluntary Bonding Scheme for medical graduates and other health professionals. The policy will provide debt relief to doctors choosing to stay in New Zealand.

Communications Skills Workshops For Doctors, Medical Defence Union, UK

The Medical Defence Union has announced that a limited number of places are remaining for its upcoming communications skills workshops for doctors taking place at its head office in London. Dr Peter Schutte, Head of Advisory Services commented, "Many of the complaints and claims seen by the MDU can be traced back to a breakdown in communication between doctor and patient.


Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .
In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture.

One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound.
The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material.

Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV.

This step can be repeated in the future in order to produce more of compound III.
Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.

Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.

At this moment Cereprotec Inc. www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.
Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.

In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.
US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.

This company is also developing a family of other promising novel chemical compounds.

Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans.
Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.

Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation") www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.
Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.

Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.

Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer.

Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union.
Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.

In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.
Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.

Pharmalef Developments www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations.
Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.

They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities.

They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.
CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008

A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/20080227838

1. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.

3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.

4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.

5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.

6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.

7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.

8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.

9. The method according to claim 8, wherein said head trauma injury is closed head injury.

10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.

11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.

12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.

13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.

14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.

15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.

16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.

17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.

18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.

19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.

20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.

21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.


Viev all previous articles...

Some Article Feeds provided by MedicalNewsToday.com

More Articles of interest...

UNC Charlotte To Evaluate Potential Adjuvant Activity Of ImmuneRegen's Viprovex(R) With Cancer Vaccine

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), today announces a collaborative relationship with the University of North Carolina at Charlotte to evaluate ImmuneRegen's Viprovex as a possible cancer-vaccine adjuvant. Adjuvants are agents that stimulate and, subsequently, augment the immune system's response to a foreign antigen. The studies will be under the direction of Pinku Mukherjee, Ph.D.

Breakthrough Optical Technology To Assess Colon Cancer Risk, Accuracy

Researchers at NorthShore University HealthSystem (NorthShore) and Northwestern University have discovered that fiber optic technology can for the very first time effectively measure blood levels in the colonic lining (mucosa) in humans, thus having potential applications for analyzing risk of colon cancer. The study appears in the October 2008 issue of Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

MethylGene Provides Update On Suspension Of New Enrollment In MGCD0103 Clinical Trials

MethylGene Inc. (TSX:MYG) announced that as a result of the internal voluntary suspension of enrollment of new patients into clinical trials evaluating MGCD0103, MethylGene and its development partner, Celgene Corporation, have been informed by the U.S.

Primarily, problems arise between sponsors and CRO-s when there are fundamental breakdowns in the delegation of responsibilities

As per ClinQua Inc. www.clinqua.com relationships exist on all levels of clinical development. Primarily, problems arise when there are fundamental breakdowns in the delegation of responsibilities or rather when someone is given control over a critical area when they are otherwise unqualified.
(613) 686-5745 Cerepotec Pharmalef

Dry Eye - Eyegate Pharma Enrolls First Dry Eye Patient In Phase II Clinical Trial Of Lead Product EGP-437

EyeGate Pharma, the leader in ocular drug delivery, a specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics to treat serious ocular diseases, today announced that it has enrolled the first dry eye patient in a Phase II safety and efficacy clinical study of EGP-437 (a combination drug/device). This patient enrollment marks the Company's second clinical trial initiated in the second half of 2008.

Addrenex Pharmaceuticals Initiates Phase 2 Trial On Its Novel Hypertension Drug, ADX415

Addrenex Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its Investigational New Drug Application (IND) for ADX415, a novel hypertension drug. With the approval, Addrenex has launched a phase 2 clinical trial to study ADX415 as a targeted therapy for hypertension. The phase 2 trial is a multicenter, double-blind, placebo-controlled, dose-ranging study that will involve 80 patients.

Enobia Pharma Receives FDA Orphan Drug Designation For Hypophosphatasia Product Candidate ENB-0040

Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, announced that it has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for ENB-0040, its enzyme replacement therapy (ERT) for hypophosphatasia, a rare, life-threatening genetic bone disease. In August 2008, Enobia dosed the first patient in a Phase I clinical trial of ENB-0040.

Kriger Research Group International joins TrialStat's CROFIRST Program

Worldwide Contract Research Organization (CRO) Deploys ClinicalAnalytics 4.0 for its Clinical Trials
(613) 686-5745 Cerepotec Pharmalef

SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI

Patients with both diabetes and advanced blockages in at least three heart vessels will find good news in new findings announced from the CARDia trial, says The Society for Cardiovascular Angiography and Interventions (SCAI). The one-year findings of the new study indicate that these patients can safely choose to undergo angioplasty and stenting rather than open-heart surgery.

Hollis-Eden Pharmaceuticals Presents Positive Updated Data From Phase I/II Clinical Trial With TRIOLEXT In Obese Insulin Resistant Subjects

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today presented additional positive interim data from its on-going Phase I/II clinical trial with its investigational oral drug candidate TRIOLEXT (HE3286) in obese insulin resistant subjects at the 6th World Congress on Insulin Resistance Syndrome, being held September 25th - 27th in Los Angeles, California. Dr. Jaime Flores-Riveros, Vice President, Endocrinology and Metabolism at Hollis-Eden Pharmaceuticals, presented the data.

Nymox's NX-1207 For The Treatment Of Benign Prostatic Hyperplasia In Phase 3 Program

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that results from the most recently completed clinical studies of NX-1207, the Company's investigational drug for the treatment of benign prostatic hyperplasia (BPH), will be presented on Thursday, September 25 at the 82nd Annual Meeting of the North Central Section of the American Urological Association being held in Chicago. Neil D. Shore, MD, FACS, of Myrtle Beach, SC will make the podium presentation.

The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity.

The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity.
(613) 686-5745 Cerepotec Pharmalef

Ironwood And Forest To Present Positive Data From Linaclotide Phase 2b IBS - C Study At ACG Annual Scientific Conference

Ironwood Pharmaceuticals (formerly Microbia) and Forest Laboratories, Inc. (NYSE: FRX) announced they will present results of a Phase 2b study investigating linaclotide's safety and efficacy in 419 patients with irritable bowel syndrome with constipation (IBS-C) in a plenary session at the American College of Gastroenterology (ACG) 2008 Annual Scientific Meeting in Orlando, Fla. on October 7, 2008.

Asenapine Meets Primary Endpoint In Long-Term Schizophrenia Relapse Prevention Trial

Schering-Plough Corporation (NYSE: SGP) announced that its novel psychopharmacologic agent asenapine has met the primary endpoint in a long-term schizophrenia relapse prevention trial. Asenapine, which is administered as a fast-dissolving sublingual tablet, is a psychopharmacologic compound with a unique human receptor signature.

ImVisioN Therapeutics Starts Phase I Clinical Trial Of IVN201 Against Cat Dander Allergy And Raises CHF 4.6 M

ImVisioN Therapeutics AG., a biopharmaceutical company pioneering intralymphatic immunotherapy (ILITT), announced that it has enrolled the first patient for a Phase I clinical study of its lead product IVN201, an immunotherapeutic product for cat dander allergy. The Company also announced the closing of a Series A Financing round of CHF 4.6 M, allowing the clinical development of IVN201.

Pharmalef Developments plays a vital role in proper documenting the drug development process.

New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.
(613) 686-5745 Cerepotec Pharmalef


Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .
In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture.

One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound.
The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material.

Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV.

This step can be repeated in the future in order to produce more of compound III.
Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.

Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.

At this moment Cereprotec Inc. www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.
Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.

In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.
US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.

This company is also developing a family of other promising novel chemical compounds.

Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans.
Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.

Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation") www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.
Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.

Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.

Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer.

Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union.
Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.

In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.
Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.

Pharmalef Developments www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations.
Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.

They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities.

They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.
CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008

A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/20080227838

1. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.

3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.

4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.

5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.

6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.

7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.

8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.

9. The method according to claim 8, wherein said head trauma injury is closed head injury.

10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.

11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.

12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.

13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.

14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.

15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.

16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.

17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.

18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.

19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.

20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.

21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.
HOME . ARTICLESMORE FEATURES .  CONTACT

613-686-5745 Clinical training is not a Scam, you should take training courses that are not a scam. Not a clinical trial scam for training in the clinical trail industry. Clinical Research Associate Courses maybe not a scam but not really a scam you learn alot about Clinic trials. Don't tell me its a scam as I think it does not work. Opinions of Clinical Training seem to say these courses are a scam. This is not truly a scam, scams are not good and clinical trails is not one of them. Take Clinical courses and you won't be scammed. Is Clinical Research Associates Training a scam? 613-686-5745

And a pair of them on 800notes.com. pharmaceutical company you hope to one day work for. Similar to comments bearing the same signature and left elsewhere, it includes talk of defamation, and “offensive or harassing content” removing this blog trinity includes a recruiting agency, a pharma company, and a school

INSTITUTIONS THAT OFFERS A PRACTICAL ORIENTED COURSE IN CLINICAL RESEARCH.ClinfoSource online GCP training courses WARN OF ONE INSTITUTE. STAY AWAY. they will help you find a job in India. certificates courses, numerous spelling and grammar mistakes. Looking for clinical research staff nation-wide to prepare and initiate clinical trials. report a fraud. report this scam. moving forward in their clinical trial as it was approved.Espoir and PharmAlef are a complete and utter fraud

qualified for any clinical trials-related positions, but we highly recommend you get a clinical trials certificate. QA experience: GMP, GLP and GCP certificate through the training and certification  programs accredited by the International Biopharmaceutical Association. Certificate form Kriger and Bachelor's degree in science and clinical research experience preferred. I am still interested in pursuing a career in clinical research. 613-686-5745

http://www.clinicaltoday.com/ . http://pharmaindustrytoday.com/ . http://www.medicaltrainingtoday.com/ . http://medicalnewspress.com . http://medicaldevicesnews.com . http://MedConferencestoday.com . http://regulatoryaffairstoday.com